Spots Global Cancer Trial Database for her2 low breast carcinoma
Every month we try and update this database with for her2 low breast carcinoma cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer | NCT05911958 | HER2 Low Breast... | SHR-A1811 for i... | 18 Years - 70 Years | Henan Cancer Hospital | |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | NCT06298084 | Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast... | Patritumab deru... Olaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer | NCT06144944 | Breast Cancer I... Hormone-recepto... HER2 Low Breast... Early-stage Bre... | Pyrotinib, epir... Placebo, epirub... | 17 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Dose-Expansion Modular Study To Explore the Safety, Tolerability, and Anti-tumor Activity of HER3- DXd Monotherapy and Combinations in Patients With Inoperable Advanced Breast Cancer (ABC) After Progression on T-DXd | NCT06298084 | Breast Cancer M... HER2-positive M... HER2 Low Breast... Advanced Breast... | Patritumab deru... Olaparib | 18 Years - | Gustave Roussy, Cancer Campus, Grand Paris | |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | NCT06224673 | HER2 Low Breast... Triple Negative... Hormone-recepto... Hormone Recepto... | ARX788 Computed Tomogr... Biospecimen Col... | 18 Years - | University of California, San Francisco | |
| Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer | NCT06144944 | Breast Cancer I... Hormone-recepto... HER2 Low Breast... Early-stage Bre... | Pyrotinib, epir... Placebo, epirub... | 17 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients | NCT05754047 | HER2 Low Breast... | immunohistochem... | - | Shahid Beheshti University of Medical Sciences | |
| Neoadjuvant Pyrotinib Versus Placebo Combined With Chemotherapy in HR-positive and HER2-low Early Breast Cancer | NCT06144944 | Breast Cancer I... Hormone-recepto... HER2 Low Breast... Early-stage Bre... | Pyrotinib, epir... Placebo, epirub... | 17 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| A Study of SHR-A1811 as Neoadjuvant Treatment for Patients With HR-Positive, Low HER2 Expression Breast Cancer | NCT05911958 | HER2 Low Breast... | SHR-A1811 for i... | 18 Years - 70 Years | Henan Cancer Hospital | |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | NCT05868226 | HER2-positive B... Metastatic Canc... Metastatic Brea... Metastatic HER2-positive M... HER2 Mutation-R... HER-2 Protein O... HER2-negative B... Triple Negative... HR Positive Hormone Recepto... Estrogen Recept... Progesterone Re... Hormone Recepto... Solid Tumor Solid Tumor, Ad... Solid Carcinoma HER2 Low Breast... HER2 Low Breast... ER Positive Bre... PR-positive Bre... | ALX148 Fam-Trastuzumab... Zanidatamab Tucatinib | 18 Years - | QuantumLeap Healthcare Collaborative | |
| ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer | NCT06224673 | HER2 Low Breast... Triple Negative... Hormone-recepto... Hormone Recepto... | ARX788 Computed Tomogr... Biospecimen Col... | 18 Years - | University of California, San Francisco |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
